Omniab, Inc. last reported quarterly results on Oct 30, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $4.0 million (+78.3% year over year) and diluted EPS of -$0.12. It usually reports 30–63 days after a quarter ends. Based on that pattern, the next release is estimated for around Mar 3, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Wednesday. Based on last year's release for the same quarter on Mar 4, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 30–63 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 30, 2026
30 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
4
+78.3%
|
-16
+4.8%
|
-0.12
+14.3%
|
|
Aug 6, 2026
37 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
13
+244.2%
|
-6
+63.1%
|
-0.05
+66.7%
|
|
May 7, 2026
37 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
14
+247.3%
|
-8
+57.7%
|
-0.06
+64.7%
|
|
Mar 4, 2026
63 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
8
-22.5%
|
-14
-8.5%
|
-0.11
+11.0%
|
|
Nov 4, 2025
35 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
2
-46.3%
|
-17
-0.9%
|
-0.14
+12.5%
|
|
Aug 6, 2025
37 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
4
-48.8%
|
-16
-16.5%
|
-0.15
-15.4%
|
|
May 8, 2025
38 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
4
+9.3%
|
-18
+4.0%
|
-0.17
+10.5%
|
|
Nov 12, 2024
43 days after quarter end
|
—
ended Sep 30, 2024
|
—
|
—
|
—
|
Company profile
- Industry
- Services-Commercial Physical & Biological Research (SIC 8731)
- Listed as
- OABI (Nasdaq), OABIW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Emeryville, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1846253
- Former names
- Avista Public Acquisition Corp. II (until Nov 1, 2022)
Other Services-Commercial Physical & Biological Research companies
- Iqvia Holdings Inc. IQV
- Incyte Corp INCY
- Medpace Holdings, Inc. MEDP
- Charles River Laboratories International, Inc. CRL
- Icon PLC ICLR
- Absci Corp ABSI
- NRC Health NRC
- Maxcyte, Inc. MXCT
All 17 Services-Commercial Physical & Biological Research companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.